Industry Trend Analysis - Johnson & Johnson To Step Up Commitment Towards Tackling Tuberculosis With New Collaboration - NOV 2017

BMI View: The high tuberculosis (TB) burden in India combined with government incentives to improve diagnosis and access to treatment, will support a greater multinational presence in the country over the long term. Johnson & Johnson ' s growing emphasis on developing potential treatments for diseases in urgent need of solutions will be supported by its new collaboration with the Institute of Microbial Technology, Chandigarh, to develop new, effective drugs for TB.

India's high tuberculosis (TB) burden will continue to present a major challenge to the country's healthcare system. According to the World Health Organization (WHO), India accounts for a little more than a quarter of the global burden of TB and has the largest number of multidrug-resistant TB cases worldwide. Against this backdrop, the Ministry of Health and Family Welfare, in its national strategic plan for tuberculosis elimination (2017-2025), has set an ambitious goal of providing quality diagnosis and treatment for all TB patients, achieving a rapid decline in the burden, morbidity and mortality of TB, while working towards elimination of TB by 2025. As a result, we expect the government will step up its efforts towards tackling the country's TB burden which will provide commercial opportunities for drugmakers and improve survival rates among the population suffering from the disease.

Johnson & Johnson To Meet Growing Healthcare Needs In India

TB: High On The Government's Agenda
Tuberculosis Burden, 2016
DALYs = disability-adjusted life years. Source: BMI's Disease Database

This article is part of our Asia coverage. To access this article subscribe now or sign up for free trial